Compare Citius Pharmaceuticals Inc (CTXR) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.32, up 5.7% in 24 hours, reflecting strong bullish momentum from its underlying asset NVIDIA. Technical indicators show a bullish trend with moving averages supporting upward movement, though the RSI suggests mild overbought conditions. Recent news highlights NVDL's leveraged exposure to NVIDIA's AI-driven growth, with the ETF capturing amplified returns from NVDA's performance, including a 12.66% year-to-date gain as of June 8, 2026, per 24/7 Wall Street.

The outlook for NVDL is tied to NVIDIA's continued dominance in AI chips, with potential for significant gains during bullish phases but high volatility risks due to daily reset leverage. Key risks include compounded losses during NVDA downturns, as seen in a 12% single-day drop on June 5, 2026. Investors should weigh the ETF's amplified returns against its inherent decay in volatile markets.